Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
Poll|Articles|May 7, 2025
Physician Survey: Assessing Cognitive Decline in Primary Care
Author(s)Patient Care Editorial Staff
Primary care clinicians are on the frontline of detecting early cognitive decline. Help us understand your challenges by taking this short survey.
Advertisement
Primary care clinicians are most often the first health care professionals to detect changes that signal potential cognitive decline. Patient Care would like to better understand your current approaches to clinical assessment of early cognitive impairment and any challenges to your screening efforts.
Results of this short survey (~2 minutes to complete) will help us focus our editorial content to your needs and interests. Thank you for participating.
Take the Physician Survey: Assessing Cognitive Decline in Primary Care
Advertisement
Related to this article
Hormone Therapy Linked to More Frequent Migraines, but Not Greater Severity, in Postmenopausal Women
TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.
FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Advertisement
Advertisement
Trending on Patient Care Online
1
4 FDA Decisions for Primary Care to Know from October 2026
2
When Night Sweats Signal Something Other Than Menopause
3
Abbott's Amulet 360 Linked to Low Stroke Risk at 1 Year in Late-Breaking Research
4
New Schizophrenia Treatment Addresses Long-Standing LAI Barriers
5